BioSpace News Archive

Excision BioTherapeutics Inc., a biotechnology company developing CRISPR-based therapies intended to cure viral infectious diseases, today announced that preclinical and bioinformatic data showing robust and specific editing of HIV proviral DNA with EBT-101 will be featured in an upcoming poster presentation at ASGCT.

Delfi Diagnostics, a pioneering developer of a new class of high-performance, affordable liquid biopsy tests for early cancer detection, has entered into a broad research agreement with Memorial Sloan Kettering Cancer Center.

Aethlon Medical, Inc., announced that it will be presenting at the H.C. Wainwright Global Investment Conference.

Iveric Bio to Present at the UBS Global Healthcare Conference 2022.

Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced four data presentations for AUSTEDO® (deutetrabenazine) tablets and TV-46000/mdc-IRM.

Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune diseases and infectious diseases, today announced that Mr. Darren Lui, President and Executive Director of Aptorum Group will present virtually at the H.C. Wainwright Global Investment Conference being held on May 23-26, 2022.

Sparrow Pharmaceuticals, an emerging, clinical-stage biopharmaceutical company developing novel, targeted therapies for disorders of corticosteroid excess, today announced that it will present new clinical pharmacology data at the 24th European Congress of Endocrinology (ECE 2022) on its lead candidate, SPI-62, an HSD-1 inhibitor.

Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI (metoclopramide) nasal spray, today announced that its management team will present at the H.C. Wainwright Global Investment Conference being held at the Fontainebleau Miami Beach Hotel from May 23-26, 2022.

Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), an innovative biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today the company will present findings from multiple studies at Digestive Disease Week® (DDW) 2022, being held May 21-24 in person in San Diego, CA and virtually.

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) and Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced an exclusive license agreement for AAV gene therapy ABO-102 (now UX111) for the treatment of Sanfilippo syndrome type A (MPS IIIA).